Literature DB >> 2407237

The selectivity of statine-based inhibitors against various human aspartic proteinases.

R A Jupp1, B M Dunn, J W Jacobs, G Vlasuk, K E Arcuri, D F Veber, D S Perlow, L S Payne, J Boger, S de Laszlo.   

Abstract

The interactions of five human enzymes (renin, pepsin, gastricsin, cathepsin D and cathepsin E) and the aspartic proteinase from Endothia parasitica with several series of synthetic inhibitors were examined. All of the inhibitors contained the dipeptide analogue statine or its phenylalanine or cyclohexylalanine homologues in the P1-P1' positions. The residues occupying the peripheral sub-sites (P4 to P3') were varied systematically and inhibitory constants were determined for the interactions with each of the proteinases. Inhibitors were elucidated that specifically inhibited human renin and did not affect any of the other human enzymes or the fungal proteinase. With suitable selection of residues to occupy individual sub-sites, effective inhibitors of specific human aspartic proteinases may now be designed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2407237      PMCID: PMC1133712          DOI: 10.1042/bj2650871

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  30 in total

1.  The determination of enzyme inhibitor constants.

Authors:  M DIXON
Journal:  Biochem J       Date:  1953-08       Impact factor: 3.857

2.  A linear equation that describes the steady-state kinetics of enzymes and subcellular particles interacting with tightly bound inhibitors.

Authors:  P J Henderson
Journal:  Biochem J       Date:  1972-04       Impact factor: 3.857

3.  Design and synthesis of a potent and specific renin inhibitor with a prolonged duration of action in vivo.

Authors:  S Thaisrivongs; D T Pals; D W Harris; W M Kati; S R Turner
Journal:  J Med Chem       Date:  1986-10       Impact factor: 7.446

4.  Synthesis of analogues of the carboxyl protease inhibitor pepstatin. Effect of structure in subsite P3 on inhibition of pepsin.

Authors:  D H Rich; M S Bernatowicz
Journal:  J Med Chem       Date:  1982-07       Impact factor: 7.446

5.  Penicillopepsin, the aspartic proteinase from Penicillium janthinellum: substrate-binding effects and intermediates in transpeptidation reactions.

Authors:  M Blum; A Cunningham; M Bendiner; T Hofmann
Journal:  Biochem Soc Trans       Date:  1985-12       Impact factor: 5.407

6.  The amino terminal amino acid sequence of human angiotensinogen.

Authors:  D A Tewksbury; R A Dart; J Travis
Journal:  Biochem Biophys Res Commun       Date:  1981-04-30       Impact factor: 3.575

7.  Renin inhibitors. Syntheses of subnanomolar, competitive, transition-state analogue inhibitors containing a novel analogue of statine.

Authors:  J Boger; L S Payne; D S Perlow; N S Lohr; M Poe; E H Blaine; E H Ulm; T W Schorn; B I LaMont; T Y Lin
Journal:  J Med Chem       Date:  1985-12       Impact factor: 7.446

8.  A systematic series of synthetic chromophoric substrates for aspartic proteinases.

Authors:  B M Dunn; M Jimenez; B F Parten; M J Valler; C E Rolph; J Kay
Journal:  Biochem J       Date:  1986-08-01       Impact factor: 3.857

9.  Pure human renin. Identification and characterization and of two major molecular weight forms.

Authors:  E E Slater; H V Strout
Journal:  J Biol Chem       Date:  1981-08-10       Impact factor: 5.157

10.  Novel renin inhibitors containing the amino acid statine.

Authors:  J Boger; N S Lohr; E H Ulm; M Poe; E H Blaine; G M Fanelli; T Y Lin; L S Payne; T W Schorn; B I LaMont; T C Vassil; I I Stabilito; D F Veber; D H Rich; A S Bopari
Journal:  Nature       Date:  1983 May 5-11       Impact factor: 49.962

View more
  8 in total

1.  Modification of the substrate specificity of porcine pepsin for the enzymatic production of bovine hide gelatin.

Authors:  C A Galea; B P Dalrymple; R Kuypers; R Blakeley
Journal:  Protein Sci       Date:  2000-10       Impact factor: 6.725

2.  Crystal structure of human pepsin and its complex with pepstatin.

Authors:  M Fujinaga; M M Chernaia; N I Tarasova; S C Mosimann; M N James
Journal:  Protein Sci       Date:  1995-05       Impact factor: 6.725

3.  Structure-based subsite specificity mapping of human cathepsin D using statine-based inhibitors.

Authors:  P Majer; J R Collins; S V Gulnik; J W Erickson
Journal:  Protein Sci       Date:  1997-07       Impact factor: 6.725

4.  Selective detection of Cathepsin E proteolytic activity.

Authors:  Wael R Abd-Elgaliel; Ching-Hsuan Tung
Journal:  Biochim Biophys Acta       Date:  2010-06-19

5.  Crystal structures of native and inhibited forms of human cathepsin D: implications for lysosomal targeting and drug design.

Authors:  E T Baldwin; T N Bhat; S Gulnik; M V Hosur; R C Sowder; R E Cachau; J Collins; A M Silva; J W Erickson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-15       Impact factor: 11.205

6.  CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity.

Authors:  E Alteri; G Bold; R Cozens; A Faessler; T Klimkait; M Lang; J Lazdins; B Poncioni; J L Roesel; P Schneider
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

Review 7.  Cathepsin D-Managing the Delicate Balance.

Authors:  Olja Mijanovic; Anastasiia I Petushkova; Ana Brankovic; Boris Turk; Anna B Solovieva; Angelina I Nikitkina; Sergey Bolevich; Peter S Timashev; Alessandro Parodi; Andrey A Zamyatnin
Journal:  Pharmaceutics       Date:  2021-06-05       Impact factor: 6.321

8.  Two crystal structures for cathepsin D: the lysosomal targeting signal and active site.

Authors:  P Metcalf; M Fusek
Journal:  EMBO J       Date:  1993-04       Impact factor: 11.598

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.